Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders

This study has been terminated.
Information provided by (Responsible Party):
Seaside Therapeutics, Inc. Identifier:
First received: October 10, 2012
Last updated: July 30, 2013
Last verified: July 2013
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: July 2013
  Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)